Evidence map›Paper›PMID 26061272›Full record

SynthesisCancer biology & therapy2015

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Domenico Ciliberto, Nicoletta Staropoli, Francesca Caglioti, Simona Gualtieri, Lucia Fiorillo, Silvia Chiellino, Antonina Maria De Angelis, Francesco Mendicino, Cirino Botta, Michele Caraglia and 2 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Domenico Cilibertoa Department of Experimental and Clinical Medicine ; Magna Græcia University ; Campus Salvatore Venuta ; Catanzaro , Italy.
Nicoletta Staropoli
Francesca Caglioti
Simona Gualtieri
Lucia Fiorillo
Silvia Chiellino
Antonina Maria De Angelis
Francesco Mendicino
Cirino Botta
Michele Caraglia
Pierfrancesco Tassone
Pierosandro Tagliaferri
Magna Graecia University · ITTemple College · USUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is still uncertain if targeted therapy-based regimens in advanced gastric cancer actually produce survival benefit. To shed light on this important question, we performed a systematic review and meta-analyses on each relevant targeted-pathway. By searching literature databases and proceedings of major cancer meetings in the time-frame 2005-2014, 22 randomized clinical trials exploring targeted therapy for a total of 7022 advanced gastric cancer patients were selected and included in the final analysis. Benefit was demonstrated for antiangiogenic agents in terms of overall survival (HR 0.759; 95%CI 0.655-0.880; p < 0.001). Conversely no benefit was found for EGFR pathway (HR 1.077; 95%CI 0.847-1.370; p = 0.543). Meta-analysis of HER-2 pathway confirmed improvement in terms of survival outcome, already known for this class of drugs (HR 0.823; 95%CI 0.722-0.939; p = 0.004). Pooled analysis demonstrated a significant survival benefit (OS: HR 0.823; PFS: HR 0.762) with acceptable tolerability profile for targeted-based therapies as compared to conventional treatments. This finding conflicts with the outcome of most individual studies, probably due to poor trial design or patients selection. In conclusion, our findings demonstrate a significant survival benefit for targeted therapy in its whole, which can be ascribed to anti-angiogenic and anti-HER2 agents.

Indexed as

Angiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansMolecular Targeted TherapyRandomized Controlled Trials as TopicStomach NeoplasmsSurvival AnalysisAngiogenesis InhibitorsEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsAb, monoclonal antibodyADME, absorption, distribution, metabolism, and excretionaGC, advanced gastric cancerangiogenesisBSC, best supportive careCHT, chemotherapyEGFR, epidermal growth factor receptorgastric cancerGC, gastric cancerHER2, human epidermal growth factor receptor 2HER3, human epidermal growth factor receptor 3meta-analysisMET, mesenchymal epithelial transition factormTORC, mTOR complexmTOR, mammalian target of rapamycinNGS, next generation sequencingNSCLC, non-small cell lung cancerOR, odds-ratioOS, overall survivalPARP, poly ADP ribose polymerasePFS, progression free survivalPI3K, phosphatidylinositide 3-kinasesPRISMA, preferred reporting items for systematic reviews and meta-analysesRAF, rapidly accelerated fibrosarcomarandomized clinical trialsRAS, rat sarcoma viral oncogene homologRCTs, randomized clinical trialsRR, response ratesystemic chemotherapytargeted pathwaystargeted therapyTKI, tyrosine kinase inhibitorVEGFR: VEGF receptorVEGF, vascular endothelial growth factor

Identifiers

PMID26061272
PMCPMC4623405
OpenAlexW1770529458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.